Tevogen Bio Holdings 株価情報 (NASDAQ: TVGN)

最新ニュース Tevogen Bio Holdings (NASDAQ:TVGN) 株価情報

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Tevogen Bio Holdings Inc

RBC Capital analyst Michael Carroll maintains Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) with a Sector Perform and lowers the price target from $128 to $117.

News

Price Target

Analyst Ratings

RBC Capital Maintains Sector Perform on Prologis, Lowers Price Target to $117

RBC Capital analyst Arun Viswanathan maintains LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) with a Sector Perform and lowers the price target from $62 to $61.

RBC Capital Maintains Sector Perform on LyondellBasell Industries, Lowers Price Target to $61

<a href="https://www.marijuanamoment.net/white-house-drug-czar-could-endorse-marijuana-legalization-under-new-bill-to-repeal-ludicrous-restriction/">https://www.marijuanamoment.net/white-house-drug-czar-could-endorse-marijuana-legalization-under-new-bill-to-repeal-ludicrous-restriction/</a>

General

MSOS

'White House Drug Czar Could Endorse Marijuana Legalization Under New Bill To Repeal 'Ludicrous' Restriction' - Marijuana Moment

RBC Capital analyst Elvira Scotto maintains Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) with a Sector Perform and raises the price target from $27 to $28.

RBC Capital Maintains Sector Perform on Kinder Morgan, Raises Price Target to $28

<a href="https://www.bloomberg.com/news/articles/2025-04-29/nike-forms-new-team-for-secretive-brand-with-kim-kardashian?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-04-29/nike-forms-new-team-for-secretive-brand-with-kim-kardashian?srnd=homepage-americas</a>

'Nike Forms New Team for Secretive Brand With Kim Kardashian'- Bloomberg

Roth MKM analyst Sean McGowan maintains Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) with a Buy and raises the price target from $21 to $24.

GRPN

Roth MKM Maintains Buy on Groupon, Raises Price Target to $24

RBC Capital analyst Michael Carroll maintains First Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FR#NYSE">FR</a>) with a Outperform and lowers the price target from $62 to $58.

RBC Capital Maintains Outperform on First Industrial Realty, Lowers Price Target to $58

RBC Capital analyst Matthew Hedberg reiterates F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) with a Sector Perform and maintains $290 price target.

Reiteration

FFIV

RBC Capital Reiterates Sector Perform on F5, Maintains $290 Price Target

RBC Capital analyst Michael Carroll maintains EastGroup Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGP#NYSE">EGP</a>) with a Sector Perform and lowers the price target from $189 to $183.

RBC Capital Maintains Sector Perform on EastGroup Properties, Lowers Price Target to $183

It is messy.
One tweet sends stock prices plummeting lower.
Another revives the hopes and dreams of beleaguered traders, and they go into a buying frenzy.
Scott Bessent gives a closed-door talk that is on the wires with a word-for-word replay almost instantly and the market rebounds.
Peter Navarro escapes from the broom closet Elon Musk shoved him into and prices collapse once again.
Most market participants are not big fans of messy markets.
Corporate executives hate the lack of clarity and cloud of uncertainty that make it impossible to fit the future into a spreadsheet.
Trading algorithms develop hiccups.
The massive increase in career risk freezes mutual funds and endowment managers in place.
Holding cash and sprinting down the halls at 50 Hudson Yards screaming &#8220;Prudent Man, Prudent Man&#8221; just might preserve that cushy job and allow the mortgage and private Pre-K tuition bills to be paid again next month.
Buying shares of a beaten-up tech stock just before an announcement of new tariffs on semiconductors could lead to a third-floor walkup on Clinton Street and Wallace Elementary School.
Mediocre performance for inaction is a much better deal than training for the Metro North to the Midtown ferry.
There is, however, one group that thrives in messy.
Activist investors, those now-gentlemanly investors that were known in days of old as corporate raiders and takeover artists, love messy.
Messy creates distortion and distortion creates opportunity.
Activists have been embracing the mess so far in 2025.
The Shareholders Advisory Group at Barclays just released its first quarter look at activism and it&#8217;s pretty clear that activists like what they see.
Despite economic storm clouds gathering on the horizon and unpredictable market volatility, the activists aren&#8217;t just staying in the game. They are doubling down.
Barclays&#8217; data shows that global campaign activity has roared ahead with 70 campaigns in Q1, jumping 17% year-over-year. More tellingly, that&#8217;s running 25% above the four-year quarterly average.
Particularly noteworthy for value-oriented investors: companies under $5 billion market cap are being targeted at an accelerated rate, representing 66% of campaigns in Q1. This tells me that activists are finding more inefficiencies and potential value in the small and mid-cap space.
Of course this is exactly where traditional value investors should be looking anyway.
An interesting small activist holding is in the portfolio of ValueAct Holdings out of San Francisco.
Over the past 25 years the firm has built up a strong track record of wins and winning board seats at target companies.
The firm has had big winners with tech companies like Microsoft (Ticker: MSFT), Adobe (Ticker: ADBE) and Salesforce (Ticker: CRM).
The firm currently owns over 4 million shares, or a little over 12% of Insight Enterprises (Ticker: NSIT). It currently has one board seat at the Information Technology company.
Insight Enterprises is a Fortune 500 global technology company founded in 1988 by brothers Tim and Eric Crown as Hard Drives International, initially selling computer storage products. The company later changed its name to Insight Enterprises in 1991, went public in 1995, and has since evolved into a comprehensive IT solutions provider with offices in 19 countries.
The business should see strong tailwinds from major trends including big data, AI, cloud computing and cyber security.
The stock has had a strong run during the time ValueAct has been involved but has had a pretty sharp decline since the start of Tariff Wars 2025 edition.
Many of Insight&#8217;s customers are governments and government agencies or in industries including healthcare and education that are seeing negative impacts from the administration policies.
The stock is currently 20% of ValueAct&#8217;s portfolio and at some point it may make sense for them to gently suggest that Insight look for a potential offer from a larger IT firm.
This could unlock some of the value of the company and give the activist an exit strategy.
Barington Capital Group is a small but scrappy activist investment firm headquartered in New York City. Founded in 2000 by James A. Mitarotonda, a former investment banker turned shareholder gadfly, Barington has built a reputation as a focused value-oriented investor that targets underperforming small- and mid-cap companies, usually with a consumer or industrial tilt.
Barington is not in the business of financial engineering or short-term flips. They&#8217;re more like value investors with an activist toolkit that is focused on long-term turnaround stories where unlocking operational or strategic inefficiencies can create a meaningful rerating.
Its current target is Matthews International (Ticker: MATW).
Matthews has a puzzling combination of businesses that include factory automation and tombstones, caskets, and cremation equipment.
It sold its packaging and branding business for $50 million earlier this year as the proxy fight heated up.
Barington lost the first round as the company was able to hold off the activist&#8217;s attempt to gain three board seats.
The company is potentially worth at least twice the current stock price, so I doubt Barington slinks away in defeat.
Like Arnold and MacArthur, they will be back.
There will be more volatility and general messiness.
It will create opportunity for activists and those who track the activists.

Opinion

ADBE

MATW

MSFT

NSIT

Under the Radar: Value Is Rising from the Ashes of Market Turmoil

Goldman Sachs analyst Matthew Sykes maintains Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) with a Buy and lowers the price target from $140 to $125.

RVTY

Goldman Sachs Maintains Buy on Revvity, Lowers Price Target to $125

<a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44569369/trump-family-tightens-grip-on-defi-platform-world-liberty-financial">World Liberty Financial</a> (WLFI), a cryptocurrency venture run by the Trump family, secured over $550 million from investors worldwide, but concerns about conflicts between presidential power and private business interests remain.
What Happened: WLFI is 60% owned by a Trump family entity and has aggressively courted investors with deals that multiple industry executives described as ethically questionable, according to an <a href="https://www.nytimes.com/2025/04/29/us/politics/trump-crypto-world-liberty-financial.html">investigation</a> published on Tuesday by The New York Times. 
The company approached at least five crypto startups offering &#8220;partnerships&#8221; that required them to purchase between $10 million and $30 million of World Liberty&#8217;s coins in exchange for smaller investments from Trump&#8217;s firm.
&#8220;It&#8217;s a black spot on our industry,&#8221; said Andre Cronje, founder of SonicLabs, which rejected World Liberty&#8217;s pitch. 
Anyone accepting such deals would &#8220;obviously think they&#8217;re going to make money because it&#8217;s the officially endorsed Trump project.&#8221;
Several startups declined these arrangements, considering them &#8220;dishonest&#8221; according to Dominik Schiener, founder of the IOTA Foundation.
World Liberty successfully secured deals with other firms, including Ondo Finance, a Peter Thiel-backed startup that later donated $1 million to Trump&#8217;s inauguration.
The company&#8217;s spokesman, David Wachsman, defended these arrangements as &#8220;standard industry practices&#8221; that establish &#8220;skin in the game for all parties,&#8221; while denying they constituted &#8220;one-sided payment for services rendered.&#8221;
Why It Matters: World Liberty&#8217;s rise coincides with Trump&#8217;s reversal on cryptocurrency. 
After previously dismissing digital assets as having value &#8220;<a href="https://www.benzinga.com/etfs/specialty-etfs/25/02/43537016/donald-trump-once-said-bitcoin-was-based-on-thin-air-now-his-media-company-is-launching-btc-etf">based on thin air</a>,&#8221; Trump has filled his administration with industry supporters, disbanded a crypto crimes task force, and announced a <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44221339/why-did-trumps-strategic-crypto-reserve-not-include-xrp">federal cryptocurrency stockpile</a> that temporarily boosted the value of World Liberty&#8217;s holdings by $33 million.
The company has attracted numerous foreign investors from Singapore, Hong Kong and the United Arab Emirates, creating a legal avenue for overseas entities to potentially curry favor with the president. 
One significant investor is Justin Sun, a Chinese billionaire facing SEC fraud charges whose case was recently suspended as the agency explores &#8220;a potential resolution.&#8221;
Eric Trump, who runs the family business with his brother Donald Trump Jr., called World Liberty &#8220;one of the more successful things we&#8217;ve ever done.&#8221;
The Trump family received 22.5 billion units of the company&#8217;s cryptocurrency — worth approximately $1.1 billion on paper.
The company&#8217;s daily operations are managed by three partners with mixed track records: Zachary Folkman, who once ran a company called Date Hotter Girls; Chase Herro, who previously promoted a cryptocurrency that imploded; and Zach Witkoff, son of Trump&#8217;s Middle East envoy Steve Witkoff.
A Trump spokeswoman told the New York Times there are &#8220;no conflicts of interest&#8221; because the president&#8217;s assets are &#8220;in a trust managed by his children,&#8221; though this trust directly benefits President Trump.
Image created using artificial intelligence.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Politics

Legal

Trump-Affiliated World Liberty Financial Defies Ethics Concerns, Raises $550 Million

RBC Capital analyst Logan Reich maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Outperform and raises the price target from $500 to $550.

RBC Capital Maintains Outperform on Domino's Pizza, Raises Price Target to $550

<ul>
<li>Companies can now use Box AI with models from IBM watsonx, including open source IBM Granite and latest from Meta's Llama</li>
<li>Box is using IBM watsonx internally to help enhance their AI governance; IBM is using Box AI to help elevate IBM employees' productivity</li>
</ul>
Box, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>), the leading Intelligent Content Management (ICM) platform, and IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) today announced they are partnering to help organizations accelerate the adoption of enterprise-level AI for content-driven workflows using IBM watsonx and Box AI. Additionally, Box is using IBMwatsonx.governance internally for life-cycle management of AI models to monitor, govern and provide guardrails for various regulations.

Box And IBM Partner To Help Organizations Accelerate Adoption Of Enterprise-level Ai For Content-driven Workflows Using IBM watsonx And Box AI

RBC Capital analyst Gregory Renza maintains CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) with a Outperform and raises the price target from $66 to $68.

CGON

RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $68

Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) shares are rising on Tuesday.
The company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45061121/hilton-reports-first-quarter-results" rel="noreferrer noopener">first-quarter adjusted earnings</a> per share of $1.72, beating the street view of $1.61. Quarterly sales of $2.69 billion missed the analyst <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus estimate of $2.72 billion</a>.
Adjusted EBITDA for the first quarter was $795 million, compared with $750 million a year ago.
Adjusted EBITDA margin expanded to 73.7% from 70.4% in the year-ago period.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44800444/goldman-sachs-cuts-outlook-for-these-hotel-and-lodging-stocks-as-potential-recession-looms" rel="noreferrer noopener">Goldman Sachs Cuts Outlook For These Hotel And Lodging Stocks As Potential Recession Looms</a>
System-wide comparable RevPAR increased 2.5%, on a currency-neutral basis, for the first quarter compared to the same period in 2024.
Quarterly net income margin expanded to 11.1% from 10.4%.
In the first quarter of 2025, the company opened 186 hotels, totaling 20,100 rooms, resulting in 14,000 net room additions.
&#8220;We continued to grow our pipeline of lifestyle properties during the quarter, adding the Tempo by Hilton brand in the U.K., marking the brand&#8217;s first hotel outside of the U.S., the first Tapestry Collection by Hilton and Curio Collection by Hilton hotels in Athens, Greece and Canopy by Hilton in Utah, representing the brand&#8217;s first ski destination,&#8221; the company said.
As of March 31, the firm had $11.2 billion of debt outstanding, excluding the deduction for deferred financing costs and discount.
Total cash and equivalents were $807 million as of March 31, 2025, including $76 million of restricted cash and cash equivalents.
The firm repurchased 3.7 million shares of Hilton common stock during the first quarter, bringing total capital return, including dividends, to $927 million for the quarter and $1,157 million year to date through April.
In April 2025, the company&#8217;s board of directors authorized a regular quarterly cash dividend of $0.15 per share of common stock to be paid on June 27.
Outlook: Hilton Worldwide raised its full-year 2025 adjusted EPS guidance to $7.76–$7.94, up from the previous range of $7.71–$7.82.
The updated full-year outlook compares with the $7.93 analyst estimate.
For the second quarter, Hilton expects adjusted EPS between $1.97 and $2.02, below the $2.11 estimate.
Price Action: HLT shares are trading lower by 1.30% to $224.27 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45065788/general-motors-margins-weaken-amid-tariff-uncertainty-ceo-barra-delays-conference-call-on-guidance-uncertainty" target="_blank" rel="noreferrer noopener">General Motors CEO Delays Earnings Call, Margins Weaken As Tariff Uncertainty Remains</a></li>
</ul>
Photo by josefkubes via Shutterstock

Earnings

Equities

Guidance

Markets

Movers

Trading Ideas

Why Is Hilton Worldwide Stock Trading Higher on Tuesday?

Goldman Sachs analyst Duffy Fischer maintains Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) with a Neutral and lowers the price target from $45 to $34.

Goldman Sachs Maintains Neutral on Dow, Lowers Price Target to $34

<a href="https://www.nuvalent.com/">Nuvalent, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>), a clinical-stage biopharmaceutical company focused on creating&nbsp;precisely&nbsp;targeted therapies for clinically proven kinase targets in cancer, today announced the publication of a manuscript in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research,&nbsp;which supports the rational molecular design of zidesamtinib, its novel and selective ROS1 inhibitor. Zidesamtinib is currently being evaluated in the ongoing ARROS-1 Phase 1/2 trial for patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors, which is designed with registrational intent for tyrosine kinase inhibitor (TKI) pre-treated and TKI-naïve patients with advanced ROS1-positive NSCLC.

NUVL

Nuvalent Publishes Study Supporting Zidesamtinib's Molecular Design in Cancer Treatment

RBC Capital analyst Anthony Codling maintains Cemex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) with a Underperform and raises the price target from $5 to $5.25.

RBC Capital Maintains Underperform on Cemex, Raises Price Target to $5.25

WIIM

Pfizer shares are trading higher following a Q1 EPS beat. The company reaffirmed guidance but said it is trending towards the upper end of its 2025 Adjusted diluted EPS guidance range.

Press Releases

Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission

Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs

Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Contracts

Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

Small Cap

WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market

Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility

Tevogen Bio Announces 2025 Annual Meeting

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

AMST

AVAI

BTAI

PLTR

TVGN

TVGNW

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Fate Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Genfit

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Inhibrx Biosciences

INmune Bio

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Korro Bio

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nanobiotix

Nkarta

Puma Biotechnology

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tango Therapeutics

Y-mAbs Therapeutics

D. Boral Capital

Tevogen Bio Holdings shares are trading higher after the company reaffirmed its oncology pipeline revenue forecast, projecting $1 billion in its launch year and a cumulative five-year estimate of $10 billion to $14 billion.

Comments

Tevogen Bio Holdings

ニュース

最新ニュース Tevogen Bio Holdings (NASDAQ:TVGN) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル